Correspondence - A commentary on ‘Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation’

Sep 21, 2026

Upload by Liam

The letter provides a correspondence-style commentary on an International Journal of Surgery study evaluating prognostic prediction of recurrence and survival after nephrectomy in patients with non-metastatic renal-cell carcinoma. It reviews the study’s prospective population-based modeling, multicenter validation, and improved predictive performance using standard clinicopathologic variables across histologic types. The authors then highlight areas needing further consideration, including definitions and management focus for locally advanced disease, lack of neoadjuvant treatment details, and potential effects of the 2019 coronavirus pandemic and its associated risks on cohort outcomes.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages2

Reading Time5 min

AccessFree to download

Correspondence

Background and study summary

Points for further consideration: locally advanced disease and neoadjuvant therapy

Cohort details and COVID-19 pandemic considerations

’Correspondence A commentary on ‘Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation’ Aimin Jiang, PhDa , Peng Luo, PhDd , Chenxin Chen, PhDc , Chen Cai, PhDb , Linhui Wang, PhDa,* Dear Editor, Renal cell carcinoma (RCC) ranks among the top 10 most prevalent cancers in both genders and is projected to have caused 81 610 new cases in the United States in 2023[1] . The assessment of tumor recurrence risk in patients with localized RCC postsurgery commonly relies on TNM stage and pathological grade. Nevertheless, individuals with identical TNM stage and pathological grade may exhibit varying outcomes, indicating that the existing staging system lacks adequate precision in predicting tumor recurrence and advising on the choice of adjuvant therapy. In light of these considerations, we have taken a keen interest in the recent publication in the International Journal of Surgery entitled ‘Predicting recurrence and survival in patients with nonmetastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation’ by Wanget al. [2] This study examines the prediction of recurrence and survival in patients with non-metastatic RCC following nephrectomy, utilizing a prospective population-based cohort for model construction and multicenter data for validation. The research delineates the creation and veriﬁcation of prognostic models integrating standard clinicopathologic variables, exhibiting enhanced predictive efﬁcacy relative to current models. Utilizing data from a substantial cohort in China and crossvalidated with a U.S.-based cohort, the study underscores the durability, precision, and prospective clinical applicability of the models across various RCC histologies. This study demonstrates notable clinical value; however, certain conclusions presented in the article warrant further contemplation. We anticipate the aDepartment of Urology, Changhai Hospital, Naval Medical University, bDepartment of Special Clinic, Changhai Hospital, Naval Medical University, cDepartment of Health Statistics, Naval Medical University, Shanghai and dDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, People’s Republic of China Aimin Jiang, Peng Luo, Chenxin Chen, and Chen Cai contributed equally to this work. Sponsorships or competing interests that maybe relevant to content are disclosed atthe end of this article. *Corresponding author. Address: Changhai Hospital, Naval Medical University, Changhai Road 168, Yangpu 200433, Shanghai, China. Tel: +86 131 280 410 12. [E-mail address: wanglinhui@smmu.edu.cn](E-mail address: wanglinhui@smmu.edu.cn) (L. Wang) Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. International Journal of Surgery (2024) 110:4433–4434 Received 26 February 2024; Accepted 3 March 2024 Published online 27 March 2024 [http://dx.doi.org/10.1097/JS9.0000000000001349](http://dx.doi.org/10.1097/JS9.0000000000001349) authors’ elucidation and reﬁnement of these ﬁndings in forthcoming research. First, in the context of RCC progression, locally advanced RCCis characterized by tumor invasion beyond the renal capsule, encompassing perinephric or renal sinus fat, while remaining within the renal fascia, potentially accompanied by regional lymph node metastasis and/or venous tumor thrombus, without distant metastasis (T1-2N1M0/T3N0-1M0 stages). Furthermore, in the absence of distant metastasis, extension beyond the renal fascia, such as adrenal invasion or involvement of adjacent organs (T4), also qualiﬁes as loca

FAQs

What study does the correspondence comment on?

It comments on the article titled “Predicting recurrence and survival in patients with non-metastatic renal-cell carcinoma after nephrectomy: a prospective population-based study with multicenter validation.”

What strengths does the letter recognize in the original research?

It emphasizes prospective model construction, multicenter validation, incorporation of standard clinicopathologic variables, and improved predictive efficiency that remains durable across RCC histologies.

Which aspects does the correspondence say need further contemplation?

It notes missing details on neoadjuvant treatments, calls attention to how locally advanced RCC is defined and managed, and highlights that pandemic-era treatment proportions and related postoperative risks were not explicitly addressed.

Sep 21, 2026

Upload by Liam